Sonovia has raised US$10 million through an IPO
December 2020 — Sonovia Ltd. has raised funds to refinance and develop the company.
Sonovia’s ground-breaking technology SonoFinishing™ helps to keep away bacteria, viruses and fungi of all kinds. It has been perfected over the years and proven in labs around the world. The company offers a commercial solution that eliminates the need for chemical binders, polymers, plastics and other harmful chemicals, and dramatically reduces the consumption of water in the process, yielding reusable and practical products and services at competitive prices.
Our role in the transaction
Oaklins’ team in Israel advised the company and acted as the leader of the distributors’ consortium.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more